Active Ingredient History
Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Colorectal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue